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Abstract
Brucella Lumazine Synthase (BLS) is a highly immunogenic decameric protein which can
accept the fusion of foreign proteins at its ten N-termini. These chimeras are very efficient to
elicit systemic and oral immunity without adjuvants. BLS signaling via Toll-Like Receptor 4
(TLR4) regulates innate and adaptive immune responses, inducing dendritic cell maturation
and CD8+ T-cell cytotoxicity. In this work we study the effect induced by BLS in TLR4-ex-
pressing B16 melanoma. In order to evaluate the effectiveness of BLS as a preventive vac-
cine, C57BL/6J mice were immunized with BLS or BLS-OVA, and 35 days later were
subcutaneously inoculated with B16-OVA melanoma. BLS or BLS-OVA induced a signifi-
cant inhibition of tumor growth, and 50% of mice immunized with the highest dose of BLS
did not develop visible tumors. This effect was not observed in TLR4-deficient mice. For
treatment experiments, mice were injected with BLS or BLS-OVA 2 days after the inocula-
tion of B16 cells. Both treatments induced significant and equal tumor growth delay and in-
creased survival. Moreover, BLS and BLS-OVA stimulation were also effective in TLR4-
deficient mice. In order to study whether BLS has a direct effect on tumor cells, B16 cells
were preincubated with BLS, and after 48h, cells were inoculated. Tumors induced by BLS-
stimulated cells had inhibited growth and survival was increased. In the BLS group, 40% of
mice did not develop tumors. This effect was abolished by the addition of TLR4/MD2 block-
ing antibody to cells before BLS stimulation. Our work demonstrates that BLS immunization
induces a preventive antitumor response that depends on mice TLR4. We also show that
BLS generates a therapeutic effect in mice inoculated with B16 cells. Our results show that
BLS acts directly in cultured tumor cells via TLR4, highly suggesting that BLS elicits its ther-
apeutic effects acting on the TLR4 from B16 melanoma cells.
Introduction
Vaccines for antitumor therapies or for the prevention of neoplasia are now in a stage of incipi-
ent development. There are many biomolecules capable of potentiate the immune response
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when co-administered with the antigen of interest, but only a few adjuvants have been ap-
proved for its use in medicine due to their toxicity. Toll-Like Receptor (TLR) agonists are of
particular interest in this area because they induce the activation of dendritic cells (DC), pro-
mote Th1-type immune responses, antigen presentation and cytotoxicity, all of which are im-
portant factors in the development of antitumor immunity [1–5]. TLR4 is particularly
important for development of a strong adaptive immune response by stimulation of the anti-
body class switching, affinity maturation, and formation of memory cells [6]. Additionally, it
has been reported that TLR4 expression by DC is a prerequisite for efficient antigen presenta-
tion of tumor antigens provided by dying cancer cells [7].
The role of TLRs in tumor development and in cancer vaccine responses is still not fully un-
derstood. Clinical and preclinical studies show that existing vaccination protocols can be im-
proved by the co-administration of TLR agonists [8–10]. The usage of high doses of these
agonists usually has toxic effects, and in some cases, TLR stimulation can also result in en-
hanced regulatory T cell proliferation and suppressor function by inhibiting NK cell cytotoxici-
ty, favoring tumor development [11–14].
In recent years it has been reported that TLR expression is not only limited to immune cells
but rather TLRs are expressed by tumor cells from different origins, both in human and mice.
Tumors exhibiting elevated TLR expression include breast, colorectal, melanoma, lung, pros-
tate, glioma, pancreatic, liver, and esophageal cancers [15–19]. Studies have correlated elevated
TLR expression and dysfunctional immunity within the tumor microenvironment with cancer
progression and reduced patient survival in a number of solid tumors [16, 20–22]. In human
melanoma it has been reported that high TLR4 expression is associated with a shortened re-
lapse-free survival [23]. Also, human myeloma cells express a broad range of TLRs, and trigger-
ing TLR7 and TLR9 induces tumor cell growth and prevents chemotherapy-induced apoptosis
[24]. These studies are of relevance because the level of TLR expression in tumors could be
used to predict the outcome of the disease and the success of potential treatments.
Bacillus Calmette-Guerin (BCG) has been used successfully for the treatment of bladder
cancer for more than 3 decades. Monthly BCG maintenance therapy improves recurrence-free
5-year cumulative survival rate [25]. BCG promotes dendritic cell maturation, and this effect is
TLR4 as well as TLR2 dependent [26]. Furthermore, BCG can induce expression of TNF relat-
ed apoptosis-inducing ligand (TRAIL) on tumor infiltrating dendritic cells, therefore rendering
them cytotoxic against tumor cells [27]. Another successful case in the use of TLR agonists in
cancer treatment is the TLR7 ligand imiquimod, approved for the topical treatment of skin
basal cell carcinoma with curative effects in a majority of patients which has been linked to acti-
vation of innate and adaptive antitumor immune mechanisms [28–30]. The combined use of
TLR agonists with therapeutic cancer vaccines or other chemotherapeutics that prime the im-
mune system for the development of Th1 cytotoxic responses against tumor antigen-express-
ing cells has yielded promising results. It has also been shown that TLR ligands can enhance
antitumor immunity in radio and chemotherapy [7].
The enzyme Lumazine Synthase from Brucella abortus (BLS) is a highly stable decameric
protein [31, 32]. It is possible to insert foreign peptides or proteins at its ten-amino acid termini
[33] and these chimeras are very efficient in generating oral and systemic immunity, even in
the absence of adjuvants, which are commonly needed in the formulation of subunit-based
vaccines. BLS has been extensively used as a carrier for peptides and proteins being a proven
successful platform for antigen presentation to the immune system for vaccine development
[34–36]. We have previously shown that BLS activates dendritic cells via TLR4, inducing the
upregulation of costimulatory molecules and the secretion of proinflamatory cytokines and
several chemokines [37]. BLS induces the cross presentation of covalently attached peptides
and generates a strong and long-lasting humoral immune response without adjuvants [38].
BLS Protection against B16 Melanoma via TLR4
PLOSONE | DOI:10.1371/journal.pone.0126827 May 14, 2015 2 / 17
Competing Interests: The authors have declared
that no competing interests exist.
B16 melanoma is a syngeneic murine melanoma derived from a spontaneously arising mel-
anoma of C57BL/6J origin [39, 40] and it is the most frequently used melanoma model in hosts
with intact immune system. In this work we use a B16-F1 cell line that expresses OVA in a
non-secreted form (B16-OVA, [41]). Human melanoma is highly curable if detected in its ear-
liest stages and treated properly; but the survival time for patients with metastatic melanoma
averages 3–15 months [42, 43]. Hence, early diagnosis and surgical removal of the primary
tumor provide the best opportunities for cure or prolonged survival to patients [44–46]. Cur-
rently, there are only a few available treatments, including surgery, chemotherapy [47, 48], IL-2
and/or IFN-α immunotherapy [49] and radiotherapy [50]. Unfortunately, there is no satisfac-
tory treatment for metastatic melanoma due to its resistance to current chemotherapy and im-
munotherapy regimens [51]. Other treatments that impact on different immunomodulatory
mechanisms, to induce an immune response against the tumor, have emerged in the last years:
anti-PD-1 and anti-CTLA4 [52, 53], BRAF and MEK inhibitors [54–56], and others. The inhi-
bition of melanogenesis has also been proposed as an adjuvant strategy in the treatment of mel-
anotic melanomas [57–60], since melanin enhances an immunosupressive environment and
protects the cells from radiotherapy [58], attenuating the treatment effect. Some DC-based vac-
cines strategies have employed DC to enhance specific immunity in preclinical models and in
clinical studies [61–65]. Although results from many clinical studies have been very encourag-
ing, treatment of metastatic melanoma remains challenging due to the difficulty to obtain
long-lasting clinical benefits, even with the novel approved drugs. There is increasing evidence
that combination therapies would generate a more effective response in a broader spectrum
of patients.
In this work we evaluate the effect of BLS stimulation in B16 melanoma growth in mice and
also whether it has a direct effect on B16 cells. The results show that BLS elicits a protective
role in mice against B16 melanoma, slowing tumor growth and prolonging mice survival.
These effects are observed when mice are immunized before tumor cells are injected and also
as a treatment, when mice are inoculated with BLS 2 days after tumor injection. The preventive
effect is dependent on mice TLR4 and the therapeutic effect is probably dependent only on
tumor TLR4. We demonstrate that stimulating B16 cells with BLS in vitro-before its inocula-
tion- significantly augments survival and that this effect is abolished when tumor cells are pre-
treated with TLR4/MD2 monoclonal antibody. BLS signaling via TLR4 could contribute to the
success of cancer treatment in combination therapies.
Materials and Methods
Protein purification
Cloning, recombinant expression, and purification of BLS protein were performed as described
previously [33, 66]. Briefly, the BLS gene was cloned into the pET11a vector (Novagen,
Madison, USA) and transformed and expressed as inclusion bodies in the BL21 (DE3) strain of
Escherichia coli. The inclusion bodies were solubilized in 50 mM Tris, 5 mM EDTA, and 8 M
urea (pH 8.0) overnight at room temperature with agitation. The solubilized material was re-
folded by dialysis against PBS containing 1 mMDTT for 72 h. This preparation was purified
with a Q-Sepharose column (Amersham Biosciences, Little Chalfont, UK) in a fast perfor-
mance liquid chromatography apparatus (Amersham Biosciences) using a linear gradient of
NaCl between 0 and 1 M in 50 mM Tris (pH 8.5). The peak enriched with BLS was further pu-
rified on a Superdex-200 column with PBS, 1 mMDTT. The purity of the BLS preparation was
determined using 15% (w/v) SDS-PAGE. BLS was concentrated (to 7 mg/ml), frozen in liquid
N2, and stored at −20°C. Purified BLS was detoxified by incubation with 1 mg of BLS with
500 μl of polymyxin B-agarose (PMB-agarose, Sigma-Aldrich, Saint Louis, MO, USA)
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overnight twice at 4°C, as previously described [37]. The procedure performed to generate BLS
chimeras was previously described [33]. To generate BLS-OVA, the coding sequence for chick-
en OVA peptide 257–264 was inserted at the N terminus of BLS in vector pet11a. The resulting
vector was transformed into and expressed in BL21 (DE3) E. coli. The chimera was purified
from bacterial cytoplasm. The purification steps were the same as those for BLS. The purity of
the samples was determined by SDS-PAGE. BLS-OVA was detoxified with PMB-agarose as de-
scribed for BLS. Limulus amebocyte lysate (LAL) test was performed in order to assure that
BLS and BLS-OVA preparations were free of LPS. Determinations were carried out following
manufacturer’s instructions (Associates of Cape Cod. Rev 002. Nov 2003. LAL Pyrotell Multit-
est vial instruction sheet). Pyrotell LAL for gel-clot assay, LAL reagent water, endotoxin stan-
dard, tips and tubes were purchased from Associates of Cape Cod (Woods Hole, MA, USA).
Mice and Cell Culture
C57BL/6J mice and C57BL/10ScNJ mice (carrying a spontaneous deletion of the Tlr4 gene)
were obtained from The Jackson Laboratory and bred in the animal facility at Leloir Institute.
All mice were bred under specific pathogen-free conditions and were used at 8–10 week of age.
B16-F1 melanoma (ATCC CRL-6323), syngeneic from C57BL/6 mice was a kind gift from Dr
José Mordoh´s lab and was cultured at 37°C under 5% CO2 in endotoxin-free RPMI 1640 me-
dium supplemented with 10% FBS (Gibco; Grand Island, NY, USA), penicillin and streptomy-
cin, 1 mM pyruvate and 4 mM L-glutamine. OVA-expressing B16-F1 melanoma (B16-OVA)
was kindly provided by Dr Paolo Dellabona [41] and was cultured in the same media with the
addition of 100 μg/ml hygromycin B (Roche Diagnostics, Mannheim, Germany).
Tumor Volume
Tumor growth was monitored every 2 or 3 days and diameters were measured using a caliper.
The major longitudinal diameter (length) and the major transverse diameter (width) were de-
termined and tumor volume was approximated based on caliper measurements by the follow-
ing formula: Tumor volume = 0.5 × (length × width2).
Vaccination and Melanoma Inoculation
In the preventive vaccination assays, C57BL/6J and C57BL/10ScNJ mice were immunized with
100 or 200 μg of BLS or 100 μg of BLS-OVA in PBS subcutaneously in the base of the tail. After
35 days, mice were inoculated with 2.5x105 B16 or B16-OVAmelanoma cells subcutaneously
in the right flank. In the treatment assays, mice were inoculated with 2.5x105 B16 or B16-OVA
cells and 2 or 10 days later were sc injected with 100 or 200 μg of BLS or 100 μg of BLS-OVA.
To study BLS direct effects on tumor cells, B16 cells were preincubated in vitro with 100 μg of
BLS or 5 ng of LPS. After 48h cells were washed 3 times with RPMI and 2.5x105 cells were sc in-
oculated in the right flank of C57BL/6J and C57BL/10ScNJ mice. To block TLR4, cells were in-
cubated with 1 μg of TLR4/MD2 monoclonal antibody (raised in rat, clone MTS510; BD
Pharmingen, San Diego, CA, USA) for 8h. Cells were then washed 3 times with RPMI and in-
cubated with BLS as described.
Apoptosis Assay
Induction of apoptosis was evaluated following Annexin V staining of adherent cells protocol
for flow cytometry. Briefly, B16 cells were cultured in a 6-well plate (2.5x105cells/well) in 2 mL
standard cell culture medium. After 18h medium was replaced and 100 μg of BLS were added.
Forty eight hours later, apoptosis was assessed using the Annexin V-PE/7-AAD detection kit
BLS Protection against B16 Melanoma via TLR4
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(#559763, BD Pharmingen, San Diego, CA, USA). Cells were gently detached using Accutase
Cell Detachment Solution (BD Biosciences; San José, CA, USA) and fluorescence-activated cell
sorter analysis was performed, as described below.
Flow Cytometry
Cells were stained with the following mAbs (BD Pharmingen, San Diego, CA, USA) and sub-
jected to FACS analysis: FITC-conjugated anti-CD80 (Hamster, clone 16-10A1), and PE-con-
jugated anti-TLR4/MD2 (Rat, clone MTS510). Cells were acquired on a FACScan cytometer
(BD Biosciences, San José, CA, USA) and data were analyzed by using CellQuest software (BD
Immunocytometry Systems, San José, CA, USA).
Ethics Statement
This study was carried out in strict accordance with the recommendations from the Guide for
the Care and Use of Laboratory Animals of the National Institutes of Health. The protocol was
approved by the Committee on the Ethics of Animal Experiments of the Leloir Institute (Proto-
col #FG58/2011). All efforts were made to minimize suffering. Mice were monitored at least
every 2 or 3 days and sacrificed by cervical dislocation when tumors reached a volume greater
than 3000 mm3, when tumors where ulcerated or signs of discomfort were observed. A small
number of animals (2–3 per experiment) inoculated with B16 cells were found dead without
previous signs of poor clinical condition. A minimum of 6 and a maximum of 10 mice were
used per group for each experiment; the total number of mice used for this work was approxi-
mately 280.
Statistical Analysis
GraphPad PRISM 5.0 software (GraphPad) was used for statistical analyses. All the experi-
ments were carried out in duplicate or triplicate and data was pooled. Statistical significance
was set at p<0.05 ( = p< 0.05,  = p< 0.01 and  = p< 0.001). Survival curves were estimat-
ed using a Kaplan-Meier plot and compared using the log-rank test. FACS results are expressed
as means ± SD; tumor volumes are shown as means ± SEM. Levels of significance were deter-
mined using unpaired two-tailed Student's t-test.
Results
Protective effect of BLS against B16 melanoma
We have previously shown that one dose of BLS without adjuvants, induces a strong innate im-
mune response via TLR4 in mice. To test whether this response is capable of preventing or
slowing tumor growth, C57BL/6J mice were immunized with a single dose of 100 or 200 μg of
BLS and 35 days later were sc injected with B16 melanoma. Non-immunized control mice de-
veloped visible tumors at 8–10 days; in contrast, immunized mice showed a significant inhibi-
tion of tumor growth where 50% of the mice immunized with a 200 μg dose, did not develop
visible tumors over a 90-day follow up. Fig 1A shows tumor growth and Fig 1B shows the sur-
vival rate. To evaluate the dependence of this protective effect on TLR4, the same experiments
were conducted in TLR4-deficient C57BL/10ScNJ mice. Immunization with BLS did not in-
duce effects in tumor growth in TLR4 deficient mice, in contrast to the same treatment in wild
type mice (Fig 1C and 1D). These results show that BLS elicits an immunoprotective response
against B16 melanoma growth via TLR4. As we have shown in a previous work, BLS induces
the cross presentation of covalently attached peptide OVA257-264 and this chimera induces
rapid activation of CTLs and a specific cytotoxic response in a TLR4-dependent manner. We
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therefore evaluated if specific response towards tumor antigens could contribute to the protec-
tive effect of BLS. To this end, mice were first immunized with the chimera BLS-OVA-consist-
ing in BLS protein decorated with 10 copies of the peptide OVA257-264- and 35 days later were
injected with an OVA-expressing B16 melanoma (B16-OVA). Surprisingly, BLS-OVA immu-
nization induced a protective effect in tumor growth but to a lesser extent than BLS (Fig 1).
This result suggests that the specific response does not generate a contribution to the overall
protective response. The reason of the obtained differences between BLS and BLS-OVA in pro-
tection remains to be studied. In our hands, the level of BMDC activation induced by BLS and
BLS-OVA do not show significant differences, inducing similar levels of costimulatory mole-
cules (S1 Fig).
Therapeutic effect of BLS vaccination
Once the partially protective effect of BLS against B16 melanoma was demonstrated, we decid-
ed to evaluate its therapeutic potential. For these experiments, mice were sc injected with BLS 2
or 10 days after the inoculation of B16 cells. Stimulation with BLS at day 10 induced a delay in
tumor growth, however, it was not significant and survival was not increased (Fig 2). BLS treat-
ment at day 2 produced a significant delay in tumor growth with both doses assayed (Fig 3A).
In accordance with this result, it was observed a significant increase in mice survival (Fig 3B).
These results show that BLS has a therapeutic protective role in mice with B16 melanoma, gen-
erating a protective response at the first stages of tumor growth but not at later stages. In con-
trast with what we observed in the preventive assays, in TLR4 deficient mice BLS induced a
similar protection than in wild type mice. This result demonstrates that the protective thera-
peutic effect is not dependent on mice TLR4 and suggests that BLS may act directly on the
Fig 1. BLS immunization induces a protective effect against B16melanoma. C57Bl/6J (C57, (A) and (B)) and C57BL/10ScNJ mice (SCN, (C) and (D))
were immunized with 100 or 200 μg of BLS or 100 μg of BLS-OVA in PBS or left untreated (control) subcutaneously in the base of the tail. After 35 days, all
mice were inoculated with 2.5x105 B16 melanoma or B16-OVA cells subcutaneously in the right flank. Tumor growth was monitored and diameters were
measured using a caliper; Tumor volume was estimated as½ (length × width2). (A) and (C) show tumor growth; (B) and (D) show the survival rate. Data from
two independent experiments with B16-OVA cells have been pooled (5 mice per group). n = 10, * p<0.05, ** p<0.01.
doi:10.1371/journal.pone.0126827.g001
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TLR4 on B16 cells. Fig 3C shows tumor growth and Fig 3D shows the survival rate in TLR4 de-
ficient mice. No statistical differences were observed between immunization with BLS-OVA or
with BLS in mice sc injected with B16-OVA cells in both strains. The effect induced by BLS is
not augmented by coupling a tumor antigen to its structure in the experimental conditions as-
sayed. In order to explain the lack of therapeutic effect when BLS is administered 10 days after
the inoculation of the tumor, the evolution of TLR4 expression in B16-OVA cells was studied:
the expression of tumor TLR4/MD2 was analyzed by FACS at different days after B16 melano-
ma inoculation in mice (Fig 4). TLR4/MD2 was expressed in 84% of B16-OVA cells before the
inoculation; in 7-day tumors it was expressed in 47.8% of the cells and this percentage dropped
Fig 2. BLS stimulation does not protect mice with B16melanoma at 10 days of tumor inoculation.
C57Bl/6J mice were inoculated with 2.5x105 B16-OVA cells sc in the right flank; 10 days later, mice were
injected sc in the base of the tail with 100 μg of BLS or BLS-OVA or left untreated (control). Tumor growth was
monitored; curves show survival rate; n = 6.
doi:10.1371/journal.pone.0126827.g002
Fig 3. BLS induces a therapeutic effect in mice with B16melanoma at 2 days of tumor inoculation. C57Bl/6J (C57, (A) and (B)) and C57BL/10ScNJ
mice (SCN, (C) and (D)) were inoculated with 2.5x105 B16 melanoma or B16-OVA cells and 2 days later were immunized with 100 or 200 μg of BLS or
100 μg of BLS-OVA or left untreated (control). Tumor growth was monitored and diameters were measured using a caliper; Tumor volume =½
(length × width2). (A) and (C) show tumor growth; (B) and (D) show the survival rate. Data from two independent experiments with B16-OVA cells have been
pooled (5 mice per group). n = 10, * p<0.05, ** p<0.01 and *** p< 0.001.
doi:10.1371/journal.pone.0126827.g003
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to 5.7% at day 10; 4.2% at day 12 and 2.6% at day 14. These results clearly show that the expres-
sion of surface TLR4/MD2 diminishes over time in vivo.
BLS impacts directly on B16 cells
It was previously reported that in vitro stimulation of B16 cells with LPS reduces subsequent
tumor growth in mice and that this effect is dependent on tumor TLR4 [67]. To study if BLS in-
duces a similar effect, B16 cells were preincubated in vitro with BLS or LPS. After 48h, cells
were washed and inoculated in C57BL/6J mice. Fig 5A shows the survival of mice injected with
B16 melanoma preincubated with BLS, LPS or unstimulated B16 cells. Tumors induced by
BLS-stimulated B16 cells had an inhibited growth compared to those induced by unstimulated
B16 cells and also with LPS-stimulated B16 cells. Remarkably, in the BLS group 40% of mice
did not develop tumors over a 120-day follow up. These results show that BLS has a direct ef-
fect in B16 cells that inhibits subsequent tumor growth. To evaluate if the TLR4 from recipient
mice had a role in this effect, the same experiment was conducted in TLR4-deficient mice. As
we expected, the extent of the inhibition of tumor growth induced by BLS prestimulation was
similar in wild type and TLR4 deficient mice (Fig 5B). This result shows that the direct effect
that BLS generates in B16 cells is independent on the presence of a functional TLR4 in mice.
We then assessed the role of the TLR4 expressed in B16 cells, TLR4/MD2 monoclonal antibody
was added to the cell culture prior to BLS stimulation. Results show that the inhibitory effect
induced by BLS is completely abolished by blocking TLR4/MD2 in B16 cells (Fig 5B and 5C).
These results clearly show that BLS triggers a mechanism in B16 cells via TLR4 that impacts in
their subsequent growth in vivo. Analysis of the apoptosis levels in BLS-stimulated B16 cells,
assessed by Annexin V/7-AAD staining and FACS analysis revealed that, as LPS, BLS did not
induce programmed cell death (Fig 6A and Table 1).
Finally, in a first attempt to address the mechanism involved in the direct effect induced by
BLS in B16 cells, we measured the levels of surface molecules after BLS stimulation. The expres-
sion of TLR4 has been reported as either increased or decreased after LPS priming depending
on cell types and experimental settings. It has been reported in several papers that B16 cells
constitutively express TLR4 and that its level first increases upon LPS stimulation [67]. There-
fore, we quantified the expression levels of TLR4/MD2 in B16 cells after 48h of stimulation
with BLS or LPS. Fig 6B shows a representative histogram of TLR4 expression in non-stimulat-
ed and stimulated-with LPS or BLS- B16 cells. The expression of cell surface TLR4 is decreased
in both stimulated groups to a similar extent. Quantification of CD80 expression levels revealed
that BLS up-regulates this costimulatory molecule (Fig 6C), suggesting that B16 cells are
Fig 4. TLR4 expression decreases in B16-OVA tumors. TLR4/MD2 expression was determined in (A): cultured B16-OVA cells and (B): excised tumors
from C57Bl/6J mice at different times post-B16-OVA sc inoculation. Representative histograms from 3 independent experiments are shown (n = 4).
doi:10.1371/journal.pone.0126827.g004
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activated upon BLS stimulation. The mean percentages of expression of TLR4 and CD80 are
shown in Table 1. Further experiments are being conducted to reveal the mechanisms that
could account for the protective effects.
Taken together, the results presented in this work show that BLS has a protective antitumor-
al effect in immunized mice and a direct effect in tumor cells. The effectiveness of the treatment
with BLS prior to tumor cell inoculation depends on mice TLR4 signaling. In contrast, the ther-
apeutic effect of BLS is independent of mice TLR4 and it is only achieved when mice are in-
jected shortly after tumor cells are injected. Finally, we have shown that BLS impacts on B16
cells via TLR4 generating a subsequent diminished tumor growth. The therapeutic effect is
probably due to the direct impact of BLS on tumor cells TLR4.
Fig 5. BLS signals B16 cells directly via TLR4. B16 cells were preincubated in vitro with 100 μg of BLS or 5
ng of LPS. After 48h cells were washed and 2.5x105 cells were sc inoculated in the right flank of C57BL/6J
mice (A). To block TLR4, cells were incubated with TLR4/MD2 monoclonal antibody; then they were
stimulated with 100 μg of BLS (BLS+TLR4/MD2 Ab) and inoculated into C57BL/10ScNJ (B) and C57Bl/6J (C)
mice. Figures show the survival rate; n = 7, * p<0.05, *** p< 0.001.
doi:10.1371/journal.pone.0126827.g005
BLS Protection against B16 Melanoma via TLR4
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Discussion
The use of TLR ligands in cancer therapy is an attractive approach that has been intensively
studied in the past years in the context of cancer treatment or prevention. It has been demon-
strated that TLR stimulation can lead to tumor regression either by direct induction of tumor
cell apoptosis [68], reducing the proliferative capacity of tumor cells [67] or by activation of an-
titumor immune responses. Indeed, TLR stimulation can activate the innate immune response
Fig 6. BLS direct effect on B16 cells. B16 cells were cultured in a 6-well plate (2.5x105cells/well) in 2 mL standard cell culture medium with 100 μg of BLS
or 5 ng of LPS for 48h. (A): Apoptosis was assessed by staining with Annexin V-PE/7-AAD and fluorescence-activated cell sorter analysis was performed.
Representative dot plots of unstimulated (control), BLS- and LPS-stimulated B16 cells are shown. (B): Expression of surface TLR4/MD2 was analyzed by
FACS in B16 melanoma. Results depict representative overlayed histograms of unstimulated (control) B16 cells, BLS- and LPS-stimulated cells. (C):
Expression of CD80 in B16 melanoma was analyzed by FACS. Representative overlayed histograms are shown of unstimulated (control) B16 cells, BLS-
and LPS-stimulated cells.
doi:10.1371/journal.pone.0126827.g006
Table 1. BLS direct effect on B16 cells.
Stimulus TLR4/MD2a,b CD80a, b Annexin V & 7-AADa, b
Positive Hi Positive Annexin V (-) 7-AAD
(+)
Annexin V (-) 7-AAD
(-)
Annexin V (+) 7-AAD
(+)
Annexin V (+) 7-AAD
(-)
control 60.5 ± 4.1 37.0 ± 2.3 20.0 ± 3.0 02.4 ± 0.3 90.4 ± 1.4 06.8 ± 0.4 00.4 ± 0.0
BLS 48.0 ± 1.8 27.4 ± 1.2 47.7 ± 6.1 03.0 ± 0.5 90.3 ± 1.8 06.2 ± 0.4 00.5 ± 0.0
LPS 43.4 ± 6.1 24.7 ± 2.6 53.8 ± 6.0 03.0 ± 0.5 88.6 ± 1.1 07.8 ± 0.2 00.5 ± 0.0
a (% ± SD)
b n = 4
doi:10.1371/journal.pone.0126827.t001
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through the activation of NK cells, DC, or macrophages and the secretion of IFN-α, IFN-γ, and
TNF-α [69–72] as well as the adaptive immune responses by favoring cross-presentation, Th1
polarization, and induction of cytotoxic T cells [73–75]. We have already described the charac-
teristics of the immune response induced by BLS and have shown that it presents many of the
desired attributes of an antitumor vaccine: (i) BLS activates DC, inducing the upregulation of
costimulatory molecules and the secretion of cytokines like IL-12p70, and TNF-α; (ii) pro-
motes the cross presentation of peptides and (iii) generates a rapid and strong in vivo specific
cytotoxicity, being most of these effects regulated by TLR4. Altogether, the results presented in
this work show that the response induced by BLS via TLR4 in vaccinated mice is able to protect
them-at least in some extent- against tumor growth. This effect would be mainly due to the in-
nate response that BLS generates, as it is not enhanced when a tumor antigen is coupled to its
structure. The capacity of BLS to activate DC, inducing the secretion of proinflamatory cyto-
kines and also activating B cells and T CD8+ cells via TLR4 may account for the observed ef-
fects in the preventive assays. We have also shown that BLS has the ability to induce the cross
presentation of covalently linked OVA peptide [38] and we have recently observed that this an-
tigen presentation continues for at least 24 days after immunization. We therefore hypothe-
sized that immunization with the chimera BLS-OVA would generate a greater inhibition of
OVA-expressing melanoma growth compared to immunization with BLS. Unexpectedly, no
differences were observed in the protective effect of BLS and BLS-OVA against B16-OVA
tumor, at least in the experimental conditions performed in this work. Treatment with BLS or
BLS-OVA of mice inoculated with B16-OVA melanoma also induced similar results. Both pro-
teins induced a delay in tumor growth and a significant increase in mice survival to a similar
extent. Maybe boost immunizations would be required to achieve an effective specific response
with a greater impact on tumor growth both in prophylactic and treatment vaccination proto-
cols; shorter times between immunization and tumor inoculation could also give better results.
In accordance with our results, Hodi et al. showed in a phase 3 study, that co-immunization
with the melanoma antigen gp100 did not improve the effect of immunotherapy with the anti-
CTLA-4 ipilimumab monoclonal antibody [76, 77]. Besides, they observed that the clinical re-
sponse in the patients treated with ipilimumab had a correlation with the occurrence of im-
mune-related adverse events. The mechanism underlying the clinical activity of CTLA-4
immunotherapy is currently under investigation, and recent experimental findings indicate
that antibody-mediated depletion of regulatory T cells (Tregs) in the tumor microenvironment
plays a key role in efficacious antitumor responses [78–80]. BLS and ipilimumab would consti-
tute different immunoregulatory therapeutic strategies sharing the common feature that specif-
ic immunity does not enhance their effect.
To address whether BLS can stimulate tumor cells directly, B16 cells were incubated in vitro
with BLS and after 48h were washed and inoculated into wild type and TLR4 deficient mice.
Remarkably, BLS-stimulated cells had a delayed growth, with a complete inhibition of tumor
growth in 40% of mice in both strains. We also showed that the effect induced by BLS is greater
than the inhibition induced by LPS. Maccioni´s group reported that LPS signaling via TLR4 on
tumor cells in vitro triggers the secretion of IFN-γ by tumor-infiltrating lymphocytes, and the
secretion of IFN-β by tumor cells, modifying tumor outgrowth in vivo [67, 81]. Our previous
results also show that immunization with one dose of 50 μg of BLS induces the expression of
IFN-γ in DLN in a TLR4-dependent way [38]. It is likely that BLS induces these cytokines se-
cretion and probably others, activating DC and CTL; the underlying mechanisms involved in
the induced response remains to be studied. We can conclude that the direct effect induced by
BLS in B16 melanoma is dependent on tumor TLR4 as this effect disappears when this receptor
is blocked with a monoclonal antibody before stimulation. Another finding supporting the di-
rect effect of BLS on tumor cells TLR4, is that the therapeutic effect correlates with the presence
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of TLR4 at the tumor´s surface. In this experimental model, TLR4 is expressed in most of the
B16 cultured cells and its level is downregulated over time in vivo. This could explain the differ-
ent outcomes of BLS treatment at day 2 or day 10 after tumor cells inoculation. Also, we have
recently assessed whether melanin was present in B16 melanoma cells and tumors in mice.
Melanin was absent in cultured B16-OVA and in tumors up to day 7 after inoculation. At day
10 after tumor inoculation, melanin was evidenced and its level increased over time between
days 10 to 14. It has been reported that melanin can attenuate treatment efficiency of radio-,
chemo-, photo-, and immunotherapy because: it has scavenging capabilities and inhibitory ef-
fects on lymphocytes [82], and that melanogenesis stimulates expression of HIF-1α, classical
HIF-1-dependent target genes involved in angiogenesis and cellular metabolism, including glu-
cose metabolism and stimulation of activity of key enzymes in the glycolytic pathway and sev-
eral other stress related genes [83]. Melanogenesis could contribute to the lack of efficacy of
BLS treatment at day 10; it would be interesting to further investigate whether the coadminis-
tration of BLS and an inhibitor of melanogenesis can induce an enhanced therapeutic outcome
compared to BLS alone. As mentioned in the Introduction, Eiro et al [23] investigated the ex-
pression and clinical relevance of various TLRs in cutaneous malignant melanoma (CMM)
from patients and found that high TLR4 expression in tumor (including tumor cells and stro-
mal cells) was significantly associated with a shortened relapse-free survival. Therefore they
state that TLR4 expression may be a prognostic factor of unfavorable evolution in CMM and
postulate TLRs and their signaling pathways as potential therapeutic targets to control tumor
progression in CMM. As BLS has a direct effect in B16 cells via TLR4, it is expected that BLS
treatment would be successful only when TLR4 is expressed in most tumor cell population. It
would be interesting to compare the effect of BLS in CMMwith high or low TLR4 expression
and evaluate whether BLS could benefit the therapy for patients with high-TLR4 CMM.
We have studied the subcellular localization of BLS by confocal microscopy in bone mar-
row-derived dendritic cells and our results show a colocalization between BLS and TLR4, first
at the cell membrane and at later times with cytoplasmic TLR4 (unpublished). These results
suggest that BLS binds to TLR4 at the plasma membrane and subsequently enters to the cyto-
plasm. We have also observed that the expression level of TLR4 first increases upon stimulation
with BLS, then decreases and lately is reestablished to control levels, as assessed by flow cytom-
etry. The shift in the surface expression level of TLR4/MD2 in dendritic cells has a correlation
with the localization of BLS and TLR4/MD2 assessed by confocal microscopy. Our hypothesis
is that BLS enters to the cytoplasm of dendritic cells with TLR4 and probably this receptor is re-
cycled, returning to the cell membrane. A similar mechanism may be responsible for the de-
creased expression of TLR4 observed in BLS-stimulated melanoma cells in vitro. It would be
interesting to study the evolution of TLR4 expression in the tumors of BLS-treated mice.
In summary, in this work we demonstrate that BLS elicits an antitumor immune response,
resulting in slower tumor growth and longer survival of the tumor-bearing hosts. Our findings
offer a new perspective on the antitumor effect of BLS that could lead to a therapeutic strategy
utilizing a TLR4 ligand. As the expression of TLR4 has been reported on a large number of tu-
mors, BLS signaling via TLR4 could make a notable contribution to the success of cancer treat-
ment when coadministered with other cancer vaccines or treatments like radiation
or chemotherapy.
Supporting Information
S1 Fig. BLS and BLS-OVA increase the level of CD86 in bone marrow dendritic cells. Ex-
pression of CD86 in CD11c+ BMDCs was analyzed by FACS after 18h of stimulation with BLS
or BLS-OVA. Representative overlayed histograms are shown of unstimulated (control), BLS-
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